Maria Deligiorgi

By Maria V. Deligiorgi and Dimitrios T. Trafalis

Illustrating the ancient link connecting inflammation with cancer, the correlation of papillary thyroid carcinoma (PTC) with Hashimoto’s thyroiditis (HT) has long been pursued as intersection of autoimmunity-induced chronic inflammation and tumor-induced immunity. The dramatic rise of the incidence of PTC οver the last decades—the main culprit for “thyroid cancer (TC) epidemic”—parallels the increasing incidence of HT, potentially reflecting a pathogenetic link that could be harnessed in diagnostics and therapeutics. Prompted by this perspective, in the present chapter, we dissect the hitherto elusive interrelationship of PTC with HT, focusing on four issues: firstly, an unresolved conundrum is whether PTC emerges due to or notwithstanding immune response or mirrors the “tumor defense-induced autoimmunity.” Secondly, the interrelationship of HT with PTC may be merely epiphenomenon of selection bias inherent in thyroidectomy series. Thirdly, the impact of HT on coexistent PTC is equivocal—host protective versus tumor protective. Fourthly, translating serum concentrations of thyroid autoantibodies and thyroid-stimulating hormone (TSH) into predictive and prognostic PTC biomarkers dichotomizes, till now, the researchers. In the era of precision medicine, illuminating whether HT precipitates PTC or vice versa is awaited with anticipation in order to refine the preventive and therapeutic policy counteracting “TC epidemic.”

Part of the book: Knowledges on Thyroid Cancer